Concarlo Therapeutics

Concarlo Therapeutics is a private preclinical oncology company developing precision medicines and companion diagnostic approaches for drug-resistant cancers. The company is built around p27 biology and seeks to modulate Cyclin-dependent kinase inhibitor 1B (p27Kip1) to inhibit Cyclin-dependent kinase 4, Cyclin-dependent kinase 6, and Cyclin-dependent kinase 2, with an initial focus on resistant estrogen receptor-positive metastatic breast cancer. Its lead therapeutic approach, IpY.20/IpY, is described as a first-in-class peptide-lipid or lipid nanoparticle formulation intended to overcome resistance to current CDK4/6-based treatment regimens. Concarlo also references a diagnostic program, ApY, to help identify patients most likely to respond. The company is headquartered in Brooklyn, New York, and appears to operate as Concarlo Holdings LLC under the commercial name Concarlo Therapeutics.